Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
With only a fifth of WHO Member States meeting their commitments to the Global Action Plan on dementia, urgent action is needed to address the escalating global dementia crisis.
In this press release, it is revealed that the World Alzheimer Report 2022 finds as many as 85 percent of people with dementia could be missing out on post-diagnosis care.
This is the press release for the World Alzheimer Report 2021 'Journey through the diagnosis of dementia'
People with dementia must be included in the priority groups for new COVID-19 vaccines, both in care homes and at home, say Alzheimer’s Disease International People with dementia are being disproportionately affected by COVID-19 and amongst most vulnerable in society Recent studies show COVID-19 deaths disproportionately affecting people with dementia;…
Dementia design in built environment is 30 years behind physical disabilities movement ADI calls on governments to embed design in their national dementia responses under the Convention on the Rights for Persons with Disabilities Dementia design follows simple principles, is cost effective and dramatically improves enjoyment and safety of built environment…
Press release on COVID-19 deaths and dementia